Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

29 source entries across 18 studies. This list may not include all unresolved or historical entries.

  • XEOMIN 200 jednotek prášek pro injekční roztokRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwańRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • XEOMEEN 200 eenheden poeder voor oplossing voor injectieRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • XEOMIN 200 egység por oldatos injekcióhozRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • XEOMIN 200 jednotiek prášok na injekčný roztokRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • XEOMIN 200 unidades polvo para solución inyectableRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • XEOMEEN 200 unités poudre pour solution injectableRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • XEOMIN 200 Einheiten Pulver zur Herstellung einer InjektionslösungRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • XEOMIN 200 unités, poudre pour solution injectableRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • XEOMIN, 200 unità, polvere per soluzione iniettabileRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • XEOMIN 200 unités, poudre pour solution injectableRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • XEOMIN 100 unités, poudre pour solution injectableRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • XEOMIN 100 unités, poudre pour solution injectableRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • XEOMIN, 100 unità, polvere per soluzione iniettabileRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • Xeomin, pulver til injektionsvæske, opløsning 100 enhederRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • Xeomin 200 unidades pó para solução injetávelRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • XEOMIN 100 unités, poudre pour solution injectableRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • XEOMIN 200 unités, poudre pour solution injectableRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • BocoutureRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INFUSION

    View study and source
  • XEOMIN 200 units powder for solution for injectionRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
11(61%)
Results Posted
200%(2 trials)

Phase Distribution

Not Applicable
3
17%
Phase 2
4
22%
Phase 3
6
33%
Phase 4
4
22%
Phase 2/3
1
6%

Phase Distribution

0

Early Stage

5

Mid Stage

10

Late Stage

Phase Distribution18 total trials
Phase 2Efficacy & side effects
4(22.2%)
Phase 2/3Combined phases
1(5.6%)
Phase 3Large-scale testing
6(33.3%)
Phase 4Post-market surveillance
4(22.2%)
N/ANon-phased studies
3(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

11

trials recruiting

Total Trials

18

all time

Status Distribution
Active(12)
Completed(1)
Other(5)

Detailed Status

Recruiting8
unknown5
Active, not recruiting3
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
11
Success Rate
100.0%

Trials by Phase

Phase 24 (22.2%)
Phase 2/31 (5.6%)
Phase 36 (33.3%)
Phase 44 (22.2%)
N/A3 (16.7%)

Trials by Status

unknown528%
completed16%
active_not_recruiting317%
recruiting844%
not_yet_recruiting16%

Recent Activity

11 active trials
Showing 5 of 18
active_not_recruitingphase_3

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

NCT03992404
active_not_recruitingphase_3

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)

NCT07210463
recruitingphase_3

Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Pelvic Pain Suggestive of Dysmenorrhea

NCT06995287
active_not_recruitingphase_3

Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)

NCT04075981
recruitingnot_applicable

Perineural Incobotulinumtoxin-A for Complex Regional Pain Syndrome - An Open-label Feasibility Study

NCT07473635
View all 18 trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT03992404Phase 3

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

Active Not Recruiting
NCT07210463Phase 3

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)

Active Not Recruiting
NCT06995287Phase 3

Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Pelvic Pain Suggestive of Dysmenorrhea

Recruiting
NCT04075981Phase 3

Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)

Active Not Recruiting
NCT07473635Not Applicable

Perineural Incobotulinumtoxin-A for Complex Regional Pain Syndrome - An Open-label Feasibility Study

Recruiting
NCT05623111Phase 2

Perineural Injections of Incobotulinumtoxin-A for Diabetic Neuropathic Pain of the Lower Extremities

Recruiting
NCT05327972Phase 2

DEgenerative ROtator Cuff Disease and Botulinum TOXin

Recruiting
NCT06499324Phase 3

Surgery with Botulinum Toxin a for Incisional Hernia

Recruiting
NCT06345677Not Applicable

Clinical Trial for the Assessment of Safety, Usability and Efficacy of the Vixe Combination for OAB in Female Subjects

Completed
NCT04220931Not Applicable

Intrapapillary Botulinum Toxin Injection for PREvention of Post-surgical PAncREactic Fistula

Recruiting
NCT05340439Phase 2

INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT)

Unknown
SYF0034f278b16a498c9ceb8eddb2ac683bPhase 2

Botulinum toxin A in the Treatment of Chronic Postsurgical Pain in Lung Cancer Patients: A feasibility study

Not Yet Recruiting
SYF0f24a0755a59457a86009f5c37337f89Phase 4

Selän alueen poikkeava aktiivisuus servikaalisessa dystoniassa

Unknown
SYF5191f9f7e72b4b738570ca2521a2f3d5Phase 3

A clinical study to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy.

Unknown
SYF7260b96b9e114e9fa615f4e945c1ed6fPhase 4

Clinical trial to see the effect and safety of botulinum toxin type A with doses adapted to patients with severe spasticity

Recruiting
SYFdd3e7527e50042d58354dd7b542f9317Phase 2/3

Satisfaction study of split doses botulinum toxin with double frequency

Unknown
SYFdeb9146f84cc419eb710348bbb677a1bPhase 4

Botox Treatment for Patients with Hidradenitis Suppurativa: A Within-Person, Randomized, Double-blind, Controlled Study

Recruiting
SYFf2d92a4e71d9417ca4702453ba8e22bdPhase 4

Prospective, randomized, blinded, comparative study between botulinum toxin and topical capsaicin in the treatment of postmastectomy syndrome. Pilot study

Unknown

All 18 trials loaded

Drug Details

Intervention Type
Type not reported
Total Trials
18